CG
BTAI icon

Cutler Group’s BioXcel Therapeutics BTAI Stock Holding History

Cutler Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-63
Closed -$2K – 3844
2022
Q4 		$2K Buy
+63
New +$15.2K ﹤0.01% 3637
2022
Q2 		– Sell
-319
Closed -$6K – 4991
2022
Q1 		$6K Buy
+319
New +$92.5K ﹤0.01% 3971
2021
Q2 		– Sell
-25
Closed -$1K – 5711
2021
Q1 		$1K Sell
25
-231
-90% -$186K ﹤0.01% 5142
2020
Q4 		$9K Sell
256
-350
-58% -$273K ﹤0.01% 3247
2020
Q3 		$46K Buy
606
+325
+116% +$244K ﹤0.01% 1845
2020
Q2 		$74K Buy
281
+50
+22% +$32.6K ﹤0.01% 1483
2020
Q1 		$10K Buy
+231
New +$83K ﹤0.01% 2705

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's BTAI Position: Q1 2024 in Review

Cutler Group reduced its BioXcel Therapeutics (BTAI) stake by 3.1% in Q1 2024, selling an estimated $286 and leaving 188 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Cutler Group first reported a position in BTAI in Q1 2020 and has held it in 16 quarters since. The position peaked at $519K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Cutler Group held 188 shares of BioXcel Therapeutics worth $8K as of Q1 2024.
  • Cutler Group sold 6 BioXcel Therapeutics shares in Q1 2024, an estimated $286.
  • BioXcel Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1361 holding.
  • Cutler Group first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Cutler Group's BioXcel Therapeutics position peaked at $519K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.